KYMR Kymera Therapeutics Inc

$KYMR Nice 10% er. To hold through earnings or not is the question....... hmmmmmm .. maybe half off the table? The earnings ive been watching seem to favor the downside this week regardless of results.

$KYMR is estimated to report earnings tomorrow before the open. I used Stock Meadow’s earnings dashboard to review its history: KYMR has beaten EPS estimates in 4 of its last 8 reports.

Oppenheimer⬆️ $KYMR's PT to $140, reiterated Outperform following early encouraging KT-579 results and sees pot'l 40%⬆️for model on +VE BROADEN2/KT-621 results. [GSK AUPH AZN RHHBY BIIB NVS BMY ABBV [REGN - SNY CRVS APGE/ABBV NKTR CLDX]] Oppenheimer said in its note: On Thursday KYMR reported convincing results from the KT-579 HV study, along with 3Q financial results. KT-579 demonstrated potent degradation of IRF-5 with doses levels 2-6 all exhibiting ≥90% degradation of the target. Management expects to go into a quiet period in the coming days with the evaluation of the BROADEN2 dataset to begin shortly. Top-line results for this key dataset in AD are on track for release before year-end. We increase our PT from $125 to $140 following these encouraging early results for '579, and see a potential further ~40% upside to our model on positive BROADEN2 results. The company ended 3Q with cash of $1.6B anticipated to support operations into 2029.

$KYMR reported earnings before the open: GAAP EPS of −$1.32 vs. −$1.26 estimated, a miss of 4.8%. I used Stock Meadow to review the results.

$KYMR Can KT-579's ≥90% IRF5 knockdown in healthy volunteers carry over to lupus patients? 🏢 Kymera Therapeutics, which makes oral protein-degrader drugs for immune diseases and was valued at about $10.19B at $122.51 a share at 16:00 ET on October 28, 2026, reported the first human results for its oral IRF5 degrader KT-579 alongside its Q3 numbers 📈 In the trial's multiple-dose part, KT-579 cut IRF5 in blood by a median of at least 90% across several dose levels, the effect stopped increasing by dose level 3, and skin showed similar reductions ⚠️ These results come from healthy volunteers and lab-stimulated blood tests rather than lupus patients, and the next step is a roughly 30-patient, 16-week biomarker study rather than an efficacy trial 📅 Next: KT-579 preclinical lupus data at ACR, November 6-11, 2026; the LUMORA lupus trial is planned to start by early 2027 Source: GlobeNewswire release + SEC 8-K, Oct 29

$KYMR Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.32 down -40.43% YoY • Reported revenue of $0M

$KYMR — Morgan Stanley Overweight, price target $146 (from $135). Information only — not investment advice. More details in our hub.

Kymera's oral STAT6 degrader KT-621: the Phase 2b BROADEN2 trial in atopic dermatitis has topline data expected by year-end 2026, with Phase 3 planned by mid-2027; cash and investments were $1.5 billion at June 30, 2026 (company, August 5, 2026). Latest company news, September 1, 2026: timing reaffirmed. More details in our $KYMR hub on our site. Not investment advice.